Clinical Trial: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of JAR-2203 in Healthy Participants (China)

China, Oct. 15 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of JAR-2203 in Healthy Participants'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134394

Registration Time: 2026/10/14

Type: Interventional study

Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=346761

Published by HT Digital Content Services with permission from Health...